This study suggests that TP53, SERPINE1, PTEN, CASP3, CREB1, CD9, and ABCC may serve as key targets for the anticancer activity of the ES and ET combination, which may possess significant biological importance in the treatment of lung cancer. This evidence concerns the gene CD9 and lung carcinoma.